Severe left atrial enlargement due to carfilzomib use in multiple myeloma
Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or adva...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2019-12, Vol.25 (8), p.2045-2048 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2048 |
|---|---|
| container_issue | 8 |
| container_start_page | 2045 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 25 |
| creator | Dasanu, Constantin A Plaxe, Steven C Popescu, Iliana M Gupta, Varun Sontz, Eric Codreanu, Ion |
| description | Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes. |
| doi_str_mv | 10.1177/1078155218825298 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179358543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155218825298</sage_id><sourcerecordid>2179358543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-c25d35a5d3abd8094d3f1781b56423aea0dfb257d89d136e0e94fba73b7add913</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlbvniTgxctqPjab7FFK1ULBgwreluxmtmxJdmuyK9Rfb0qrQsHLzMA8887Mi9AlJbeUSnlHiVRUCEaVYoLl6giNaSplQnL2fhzr2E62_RE6C2FFCFGSqVM04iTjmWBqjOYv8AkesIW6x7r3jbYYWqv9Ehy0PTYD4L7DlfZ1Y78615R4CICbFrvB9s3aAnYbsJ3T5-ik1jbAxT5P0NvD7HX6lCyeH-fT-0VSxZV9UjFhuNAx6NIokqeG1zR-UYosZVyDJqYumZBG5YbyDAjkaV1qyUupjckpn6Cbne7adx8DhL5wTajAWt1CN4SCUZlzoUTKI3p9gK66wbfxuoJxylIlU7GlyI6qfBeCh7pY-8ZpvykoKbY2F4c2x5GrvfBQOjC_Az--RiDZAUEv4W_rv4LfL3-EEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2312487453</pqid></control><display><type>article</type><title>Severe left atrial enlargement due to carfilzomib use in multiple myeloma</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Dasanu, Constantin A ; Plaxe, Steven C ; Popescu, Iliana M ; Gupta, Varun ; Sontz, Eric ; Codreanu, Ion</creator><creatorcontrib>Dasanu, Constantin A ; Plaxe, Steven C ; Popescu, Iliana M ; Gupta, Varun ; Sontz, Eric ; Codreanu, Ion</creatorcontrib><description>Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155218825298</identifier><identifier>PMID: 30636528</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Cardiotoxicity - etiology ; Enlargement ; Heart ; Heart Atria - drug effects ; Heart Atria - pathology ; Humans ; Inhibitor drugs ; Male ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Oligopeptides - administration & dosage ; Oligopeptides - adverse effects ; Targeted cancer therapy</subject><ispartof>Journal of oncology pharmacy practice, 2019-12, Vol.25 (8), p.2045-2048</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-c25d35a5d3abd8094d3f1781b56423aea0dfb257d89d136e0e94fba73b7add913</citedby><cites>FETCH-LOGICAL-c365t-c25d35a5d3abd8094d3f1781b56423aea0dfb257d89d136e0e94fba73b7add913</cites><orcidid>0000-0003-0425-8394</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155218825298$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155218825298$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,21800,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30636528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dasanu, Constantin A</creatorcontrib><creatorcontrib>Plaxe, Steven C</creatorcontrib><creatorcontrib>Popescu, Iliana M</creatorcontrib><creatorcontrib>Gupta, Varun</creatorcontrib><creatorcontrib>Sontz, Eric</creatorcontrib><creatorcontrib>Codreanu, Ion</creatorcontrib><title>Severe left atrial enlargement due to carfilzomib use in multiple myeloma</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.</description><subject>Aged</subject><subject>Cardiotoxicity - etiology</subject><subject>Enlargement</subject><subject>Heart</subject><subject>Heart Atria - drug effects</subject><subject>Heart Atria - pathology</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oligopeptides - adverse effects</subject><subject>Targeted cancer therapy</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlbvniTgxctqPjab7FFK1ULBgwreluxmtmxJdmuyK9Rfb0qrQsHLzMA8887Mi9AlJbeUSnlHiVRUCEaVYoLl6giNaSplQnL2fhzr2E62_RE6C2FFCFGSqVM04iTjmWBqjOYv8AkesIW6x7r3jbYYWqv9Ehy0PTYD4L7DlfZ1Y78615R4CICbFrvB9s3aAnYbsJ3T5-ik1jbAxT5P0NvD7HX6lCyeH-fT-0VSxZV9UjFhuNAx6NIokqeG1zR-UYosZVyDJqYumZBG5YbyDAjkaV1qyUupjckpn6Cbne7adx8DhL5wTajAWt1CN4SCUZlzoUTKI3p9gK66wbfxuoJxylIlU7GlyI6qfBeCh7pY-8ZpvykoKbY2F4c2x5GrvfBQOjC_Az--RiDZAUEv4W_rv4LfL3-EEg</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Dasanu, Constantin A</creator><creator>Plaxe, Steven C</creator><creator>Popescu, Iliana M</creator><creator>Gupta, Varun</creator><creator>Sontz, Eric</creator><creator>Codreanu, Ion</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0425-8394</orcidid></search><sort><creationdate>201912</creationdate><title>Severe left atrial enlargement due to carfilzomib use in multiple myeloma</title><author>Dasanu, Constantin A ; Plaxe, Steven C ; Popescu, Iliana M ; Gupta, Varun ; Sontz, Eric ; Codreanu, Ion</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-c25d35a5d3abd8094d3f1781b56423aea0dfb257d89d136e0e94fba73b7add913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Cardiotoxicity - etiology</topic><topic>Enlargement</topic><topic>Heart</topic><topic>Heart Atria - drug effects</topic><topic>Heart Atria - pathology</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oligopeptides - adverse effects</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dasanu, Constantin A</creatorcontrib><creatorcontrib>Plaxe, Steven C</creatorcontrib><creatorcontrib>Popescu, Iliana M</creatorcontrib><creatorcontrib>Gupta, Varun</creatorcontrib><creatorcontrib>Sontz, Eric</creatorcontrib><creatorcontrib>Codreanu, Ion</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dasanu, Constantin A</au><au>Plaxe, Steven C</au><au>Popescu, Iliana M</au><au>Gupta, Varun</au><au>Sontz, Eric</au><au>Codreanu, Ion</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe left atrial enlargement due to carfilzomib use in multiple myeloma</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2019-12</date><risdate>2019</risdate><volume>25</volume><issue>8</issue><spage>2045</spage><epage>2048</epage><pages>2045-2048</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>30636528</pmid><doi>10.1177/1078155218825298</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0425-8394</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2019-12, Vol.25 (8), p.2045-2048 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179358543 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Aged Cardiotoxicity - etiology Enlargement Heart Heart Atria - drug effects Heart Atria - pathology Humans Inhibitor drugs Male Multiple myeloma Multiple Myeloma - drug therapy Oligopeptides - administration & dosage Oligopeptides - adverse effects Targeted cancer therapy |
| title | Severe left atrial enlargement due to carfilzomib use in multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A31%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20left%20atrial%20enlargement%20due%20to%20carfilzomib%20use%20in%20multiple%20myeloma&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Dasanu,%20Constantin%20A&rft.date=2019-12&rft.volume=25&rft.issue=8&rft.spage=2045&rft.epage=2048&rft.pages=2045-2048&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155218825298&rft_dat=%3Cproquest_cross%3E2179358543%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2312487453&rft_id=info:pmid/30636528&rft_sage_id=10.1177_1078155218825298&rfr_iscdi=true |